Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06048523
Other study ID # CHUBX 2022/73
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 2023
Est. completion date July 2026

Study information

Verified date September 2023
Source University Hospital, Bordeaux
Contact Chloe ANGELINI, MD
Phone +335 56 79 59 52
Email chloe.angelini@chu-bordeaux.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Neurogenetic diseases (NGD) represent rare and hereditary forms of neurological diseases. The goal of CNGD is to create a one-window approach for NGDs, to facilitate and accelerate participation in research projects through deep phenotyping and the availability of low-cost biological samples for research teams. It is positioned as a true hub allowing new connections between clinical and basic research teams and ultimately as an incubator for translational projects for NGDs, in order to be able to initiate therapeutic trials, the ultimate objective of clinical and translational research.


Description:

Neurogenetic diseases (NGDs) represent rare inherited forms of neurological diseases. They constitute a constellation of different diseases, affecting neurodevelopment (syndromic or non-syndromic intellectual disabilities (ID), with or without autism spectrum disorders (ASD), epileptic encephalopathies, neurodevelopmental disorders (NDD) with or without ID... ) or leading to early neurodegeneration (Huntington's and Huntington-like disease, hereditary ataxias, hereditary spastic paraplegias (HSP), primary dystonias, neurodegeneration due to intracerebral iron accumulation (NBIA), neurometabolic diseases, etc.). Progress in the knowledge of the genetic causes of NGDs is unceasing, with the discovery of new genes involved in their determinism being continuous. As a result, the boundary between routine care and clinical research is extremely narrow and blurred, and the two activities are totally intertwined and interdependent in the care of patients. For patients with NGDs already characterized by molecular genetics, at an early, intermediate or presymptomatic stage, we will perform a comprehensive annual standardized clinical and paraclinical evaluation for deep phenotyping as part of routine care; collection of biological samples (annual blood and urine sampling, optional skin biopsy and optional cerebrospinal fluid (CSF) sampling), for functional analyses and better understanding of the pathophysiological mechanisms involved. This study will last 3 years


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date July 2026
Est. primary completion date July 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Years and older
Eligibility Inclusion Criteria: - Patient-specific inclusion criteria - Age = 6 years - Patient with a molecularly identified NGD o Specific inclusion criteria for controls - For the 10 controls with lumbar puncture (LP): person who performed an LP for medical reasons and who consented to participate in the collection of biological samples - Age = 18 years - Person matched in age (+/- 5 years) and sex to adult patient with NGD at the time of collection Exclusion Criteria: - Participation in an interventional clinical trial that may interfere with our study - Refusal of blood collection - Pregnant and breastfeeding women - Only for patients performing LP: Contraindication to LP - Specific non-inclusion criteria for controls: Criterion of a neurodegenerative or inflammatory pathology of the central nervous system

Study Design


Intervention

Procedure:
Patient cohort
For patients: annual follow-up in Neurogenetic reference center, as part of routine care, with exhaustive standardised clinical evaluation Paraclinical monitoring (e.g. MRI, EEG, EMG, etc.) modelled on standard care according to current recommendations Biological samples offered to patients in the context of research: Annual blood sample Annual urine sample Collection of 1 skin biopsy at the inclusion visit (for 30 patients) Cerebrospinal fluid sample at the inclusion visit (for 15 patients
Control cohort
controls without LP: 1 visit for blood, urine and optional skin biopsy controls with LP: additional blood and cerebrospinal fluid tubes for blood sampling and LP as part of routine care, without longitudinal follow-up

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Outcome

Type Measure Description Time frame Safety issue
Primary Constitution of a biobank of NGD patients correlated with clinical data Number of participants for whom minimum clinical data have been collected and for whom at least one at least one protocol sample has been collected Inclusion visit, 12 months visit and 24 months visit
See also
  Status Clinical Trial Phase
Completed NCT05086809 - Investigation of an Updated Bone-anchored Sound Processor N/A
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Recruiting NCT03222375 - SQUEDâ„¢ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism N/A
Completed NCT03295786 - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease Phase 1/Phase 2
Completed NCT01922258 - Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Phase 3
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Completed NCT02798406 - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects Phase 2
Suspended NCT04912115 - Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia Phase 2
Completed NCT03994822 - pRESET for Occlusive Stroke Treatment N/A
Completed NCT03336645 - Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan Phase 3
Completed NCT04283253 - Predictors of Response in Chronic Stroke N/A
Completed NCT02684825 - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke N/A
Active, not recruiting NCT02284126 - Topical Vancomycin for Neurosurgery Wound Prophylaxis Phase 3
Completed NCT05815836 - Precision Medicine in Stroke
Completed NCT00739518 - Refinement and Assessment of New Magnetic Resonance Imaging Technologies for Neurological Exams N/A
Recruiting NCT03678194 - Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application N/A
Recruiting NCT04698421 - Collection of Biological Samples From Patients With Rare Neurological Diseases
Recruiting NCT06111898 - Neuro-biomechanical Determinants for Motor Behavior in High-risk Infants